Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for prevention and treatment of thromboembolic diseases. Although routine monitoring will not be required, in certain situations assessment of drug level may be helpful. This study evaluated the suitability of comme...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Thrombosis and haemostasis Ročník 104; číslo 6; s. 1263
Hlavní autori:	Barrett, Yu Chen, Wang, Zhaoqing, Frost, Charles, Shenker, Andrew
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Germany 01.12.2010
Predmet:	Anticoagulants - blood Anticoagulants - therapeutic use Blood Coagulation - drug effects Blood Coagulation Tests Clinical Trials, Phase II as Topic Dose-Response Relationship, Drug Drug Monitoring - methods Factor Xa Inhibitors Humans International Normalized Ratio Isoxazoles - blood Morpholines - blood Predictive Value of Tests Prothrombin Time Pyrazoles - blood Pyrazoles - therapeutic use Pyridones - blood Pyridones - therapeutic use Reproducibility of Results Rivaroxaban Thiophenes - blood Venous Thromboembolism - blood Venous Thromboembolism - drug therapy
ISSN:	0340-6245, 2567-689X, 2567-689X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!